Drugs / AMC303
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03009214 | Dec 2016 → Jul 2020 | cancer | amcure GmbH | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AMC303 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03009214 ↗ |
| Action | Inhibit | “inhibitor blocking receptor tyrosine kinase (RTK) pathways” NCT03009214 ↗ |
| Route | Intravenous | “as intravenous infusion” NCT03009214 ↗ |